Profile: Obseva SA (OBSV.OQ)
Obseva SA, incorporated on November 14, 2012, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for serious conditions that compromises a woman’s reproductive health and pregnancy. It is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions. The Company is developing a pipeline of orally-administered new chemical entities (NCEs) for the treatment of symptoms associated with endometriosis and uterine fibroids.
The Company develops OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials). It develops nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF. Nolasiban is in phase 3 of clinical trials. It also develops OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor from 24 to 34 weeks gestational age. The Company’s subsidiaries include ObsEva USA, Inc. and ObsEva Ireland Limited. OBE022 is in phase 2a of clinical trials.
The Company competes with AbbVie Inc., Myovant Sciences, Inc. and Astellas Pharma Inc.
Chemin des Aulx 12